Glatiramer — Membership Pricing

Other medications in Neurological

• Interferon Beta-1a
• Interferon Beta-1b
• Lacosamide
• Lasmiditan
• Meclizine
• Memantine
• Midazolam Nasal
• Natalizumab (Neurology)

About Glatiramer

Glatiramer acetate is a widely recognized medication primarily used in the treatment of Multiple Sclerosis (MS). Specifically, it's approved for individuals with relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS). MS is an autoimmune disease where the body's immune system mistakenly attacks the protective sheath (myelin) covering nerve fibers, leading to communication problems between your brain and the rest of your body. Symptoms can vary widely but often include fatigue, numbness, muscle weakness, vision problems, and issues with coordination.

How Glatiramer Works

Unlike some other MS treatments that suppress the entire immune system, glatiramer is considered an immunomodulator. Its exact mechanism of action is not fully understood, but it's believed to work by mimicking a component of myelin, called myelin basic protein. By doing so, it's thought to divert the immune system's attack away from the body's own myelin. This process helps to reduce the frequency of MS relapses and may slow the progression of disability in some patients. Glatiramer is typically administered as a subcutaneous injection, either daily or three times a week, depending on the dosage prescribed.

Understanding Typical Costs

Glatiramer, available under brand names like Copaxone and as generic versions such as Glatopa, can be a significant financial burden due to its high cost. The price can vary widely based on the specific formulation (20mg daily vs. 40mg three times a week), the pharmacy you use, your insurance coverage, and whether you opt for the brand-name or generic version. Without insurance or significant discounts, the monthly cost can

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Glatiramer is approved for (FDA label)

Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ).

Source: Read the full FDA label on DailyMed. Label effective date: February 7, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Glatiramer (FDA label)

WARNING: ANAPHYLACTIC REACTIONS Cases of life-threatening and fatal anaphylaxis have been reported with glatiramer acetate injection. Anaphylaxis can occur at any time following initiation of therapy, from as early as after the first dose, up to years following initiation of therapy. • Make patients aware of the symptoms of anaphylaxis, which may overlap with those of an immediate post-injection reaction; instruct them to seek immediate medical care should these symptoms occur. Prompt identification of anaphylaxis is important to avoid a delay in treatment [see Warnings and Precautions (5.1) ] . • Glatiramer acetate injection is contraindicated in patients with a history of hypersensitivity reactions to glatiramer acetate injection, including anaphylaxis. If an anaphylactic reaction occurs, treatment with glatiramer acetate injection must be immediately discontinued. Unless a clear alternative etiology is identified, glatiramer acetate injection must be permanently discontinued [see Contraindications (4) and Warnings and Precautions (5.1) ] . WARNING: ANAPHYLACTIC REACTIONS See full prescribing information for complete boxed warning. Life-threatening and fatal anaphylaxis, which can occur at any time following initiation of therapy (from as early as after the first dose, up to years after initiation of treatment), has been reported in patients receiving glatiramer acetate injection. • Make patients aware of the symptoms of anaphylaxis, which may overlap with those of an immediate post-injection reaction. Prompt identification of anaphylaxis is important to avoid a delay in treatment ( 5.1 ).

Source: FDA prescribing information (DailyMed). Set ID: 456a34c7-8511-4000-99a7-ad8f8de6d35e. SPL document ID: f5070abd-2219-47fa-8ff2-c0b147ea3eb7. Label effective date: February 7, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Glatiramer (FDA label)

• Injection: 40 mg per mL in a single-dose, prefilled syringe with a light blue plunger. For subcutaneous use only. • Injection: 40 mg/mL in a single-dose, prefilled syringe with a light blue plunger ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 456a34c7-8511-4000-99a7-ad8f8de6d35e. SPL document ID: f5070abd-2219-47fa-8ff2-c0b147ea3eb7. Label effective date: February 7, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Glatiramer (FDA label)

The following serious adverse reactions are described elsewhere in the labeling: • Anaphylactic Reactions [see Warnings and Precautions (5.1) ] • Immediate Post-Injection Reaction [see Warnings and Precautions (5.2) ] • Chest Pain [see Warnings and Precautions (5.3) ] • Lipoatrophy and Skin Necrosis [see Warnings and Precautions (5.4) ] • Potential Effects on Immune Response [see Warnings and Precautions (5.5) ] • Hepatic Injury [see Warnings and Precautions (5.6) ] • In controlled studies of glatiramer acetate injection 20 mg/mL, most common adverse reactions (≥ 10% and ≥ 1.5 times higher than placebo) were: injection site reactions, vasodilatation, rash, dyspnea, and chest pain ( 6.1 ) • In a controlled study of glatiramer acetate injection 40 mg/mL, most common adverse reactions (≥ 10% and ≥ 1.5 times higher than placebo) were: injection site reactions ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 456a34c7-8511-4000-99a7-ad8f8de6d35e. SPL document ID: f5070abd-2219-47fa-8ff2-c0b147ea3eb7. Label effective date: February 7, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Glatiramer (FDA label)

Glatiramer acetate injection is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol. Reactions have included anaphylaxis [see Warnings and Precautions (5.1) ] . Known hypersensitivity to glatiramer acetate or mannitol ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 456a34c7-8511-4000-99a7-ad8f8de6d35e. SPL document ID: f5070abd-2219-47fa-8ff2-c0b147ea3eb7. Label effective date: February 7, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Glatiramer (FDA label)

• Immediate Post-Injection Reaction (flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and/or urticaria), may occur within seconds to minutes after injection and are generally transient and self-limiting ( 5.2 ) • Chest pain, usually transient ( 5.3 ) • Lipoatrophy and skin necrosis may occur.

Source: FDA prescribing information (DailyMed). Set ID: 456a34c7-8511-4000-99a7-ad8f8de6d35e. SPL document ID: f5070abd-2219-47fa-8ff2-c0b147ea3eb7. Label effective date: February 7, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.